BACKGROUND: Cortical-bone fragility is a common feature in osteoporosis that is linked to nonvertebral fractures. Regulation of cortical-bone homeostasis has proved elusive. The study of genetic disorders of the skeleton can yield insights that fuel experimental therapeutic approaches to the treatment of rare disorders and common skeletal ailments. METHODS: We evaluated four patients with Pyle's disease, a genetic disorder that is characterized by cortical-bone thinning, limb deformity, and fractures; two patients were examined by means of exome sequencing, and two were examined by means of Sanger sequencing. After a candidate gene was identified, we generated a knockout mouse model that manifested the phenotype and studied the mechanisms responsible for altered bone architecture. RESULTS: In all affected patients, we found biallelic truncating mutations in SFRP4, the gene encoding secreted frizzled-related protein 4, a soluble Wnt inhibitor. Mice deficient in Sfrp4, like persons with Pyle's disease, have increased amounts of trabecular bone and unusually thin cortical bone, as a result of differential regulation of Wnt and bone morphogenetic protein (BMP) signaling in these two bone compartments. Treatment of Sfrp4-deficient mice with a soluble Bmp2 receptor (RAP-661) or with antibodies to sclerostin corrected the cortical-bone defect. CONCLUSIONS: Our study showed that Pyle's disease was caused by a deficiency of sFRP4, that cortical-bone and trabecular-bone homeostasis were governed by different mechanisms, and that sFRP4-mediated cross-regulation between Wnt and BMP signaling was critical for achieving proper cortical-bone thickness and stability. (Funded by the Swiss National Foundation and the National Institutes of Health.).
BACKGROUND: Cortical-bone fragility is a common feature in osteoporosis that is linked to nonvertebral fractures. Regulation of cortical-bone homeostasis has proved elusive. The study of genetic disorders of the skeleton can yield insights that fuel experimental therapeutic approaches to the treatment of rare disorders and common skeletal ailments. METHODS: We evaluated four patients with Pyle's disease, a genetic disorder that is characterized by cortical-bone thinning, limb deformity, and fractures; two patients were examined by means of exome sequencing, and two were examined by means of Sanger sequencing. After a candidate gene was identified, we generated a knockout mouse model that manifested the phenotype and studied the mechanisms responsible for altered bone architecture. RESULTS: In all affected patients, we found biallelic truncating mutations in SFRP4, the gene encoding secreted frizzled-related protein 4, a soluble Wnt inhibitor. Mice deficient in Sfrp4, like persons with Pyle's disease, have increased amounts of trabecular bone and unusually thin cortical bone, as a result of differential regulation of Wnt and bone morphogenetic protein (BMP) signaling in these two bone compartments. Treatment of Sfrp4-deficient mice with a soluble Bmp2 receptor (RAP-661) or with antibodies to sclerostin corrected the cortical-bone defect. CONCLUSIONS: Our study showed that Pyle's disease was caused by a deficiency of sFRP4, that cortical-bone and trabecular-bone homeostasis were governed by different mechanisms, and that sFRP4-mediated cross-regulation between Wnt and BMP signaling was critical for achieving proper cortical-bone thickness and stability. (Funded by the Swiss National Foundation and the National Institutes of Health.).
Authors: Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty Journal: Dev Cell Date: 2005-05 Impact factor: 12.270
Authors: Eveline Boudin; Elke Piters; Igor Fijalkowski; Gino Stevenheydens; Ellen Steenackers; Outi Kuismin; Jukka S Moilanen; Geert Mortier; Wim Van Hul Journal: Bone Date: 2012-10-06 Impact factor: 4.398
Authors: Matthew L Warman; Valerie Cormier-Daire; Christine Hall; Deborah Krakow; Ralph Lachman; Martine LeMerrer; Geert Mortier; Stefan Mundlos; Gen Nishimura; David L Rimoin; Stephen Robertson; Ravi Savarirayan; David Sillence; Juergen Spranger; Sheila Unger; Bernhard Zabel; Andrea Superti-Furga Journal: Am J Med Genet A Date: 2011-03-15 Impact factor: 2.802
Authors: Rutger L van Bezooijen; Bernard A J Roelen; Annemieke Visser; Lianne van der Wee-Pals; Edwin de Wilt; Marcel Karperien; Herman Hamersma; Socrates E Papapoulos; Peter ten Dijke; Clemens W G M Löwik Journal: J Exp Med Date: 2004-03-15 Impact factor: 14.307
Authors: Phillip C Witcher; Sara E Miner; Daniel J Horan; Whitney A Bullock; Kyung-Eun Lim; Kyung Shin Kang; Alison L Adaniya; Ryan D Ross; Gabriela G Loots; Alexander G Robling Journal: JCI Insight Date: 2018-06-07
Authors: Long Guo; Débora Romeo Bertola; Asako Takanohashi; Asuka Saito; Yuko Segawa; Takanori Yokota; Satoru Ishibashi; Yoichiro Nishida; Guilherme Lopes Yamamoto; José Francisco da Silva Franco; Rachel Sayuri Honjo; Chong Ae Kim; Camila Manso Musso; Margaret Timmons; Amy Pizzino; Ryan J Taft; Bryan Lajoie; Melanie A Knight; Kenneth H Fischbeck; Andrew B Singleton; Carlos R Ferreira; Zheng Wang; Li Yan; James Y Garbern; Pelin O Simsek-Kiper; Hirofumi Ohashi; Pamela G Robey; Alan Boyde; Naomichi Matsumoto; Noriko Miyake; Jürgen Spranger; Raphael Schiffmann; Adeline Vanderver; Gen Nishimura; Maria Rita Dos Santos Passos-Bueno; Cas Simons; Kinya Ishikawa; Shiro Ikegawa Journal: Am J Hum Genet Date: 2019-04-11 Impact factor: 11.025
Authors: S Blouin; N Fratzl-Zelman; A Roschger; W A Cabral; K Klaushofer; J C Marini; P Fratzl; P Roschger Journal: J Mech Behav Biomed Mater Date: 2018-10-11
Authors: Roy B Choi; Whitney A Bullock; April M Hoggatt; Daniel J Horan; Emily Z Pemberton; Jung Min Hong; Xinjun Zhang; Xi He; Alexander G Robling Journal: J Bone Miner Res Date: 2021-07-23 Impact factor: 6.741
Authors: Matthias B Moor; Suresh K Ramakrishnan; Finola Legrand; Silvia Dolder; Mark Siegrist; Fanny Durussel; Gabriel Centeno; Dmitri Firsov; Nancy E Hynes; Willy Hofstetter; Olivier Bonny Journal: JBMR Plus Date: 2018-01-17